Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AS1810722 is an orally active and potent STAT6 inhibitor(IC50 :1.9 nM). AS1810722 shows a good profile of CYP3A4 inhibition. AS1810722, a derivative of fused bicyclic pyrimidine, has the potential for allergic diseases such as asthma and atopic diseases research.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 115.00 | |
5 mg | In stock | $ 247.00 | |
10 mg | In stock | $ 397.00 | |
25 mg | In stock | $ 663.00 | |
50 mg | In stock | $ 945.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 259.00 |
Description | AS1810722 is an orally active and potent STAT6 inhibitor(IC50 :1.9 nM). AS1810722 shows a good profile of CYP3A4 inhibition. AS1810722, a derivative of fused bicyclic pyrimidine, has the potential for allergic diseases such as asthma and atopic diseases research. |
Targets&IC50 | STAT6:1.9 nM |
In vitro | AS1810722 showed potent STAT6 inhibition and a good CYP3A4 inhibition profile.?AS1810722 also inhibited in vitro Th2 differentiation without affecting type 1 helper T (Th1) cell differentiation and eosinophil infiltration in an antigen-induced mouse asthmatic model after oral administration. |
Molecular Weight | 477.51 |
Formula | C25H25F2N7O |
CAS No. | 909561-15-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 62.5 mg/mL (130.89 mM), sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
AS1810722 909561-15-5 JAK/STAT signaling Metabolism Stem Cells P450 STAT inhibit CYPs AS-1810722 Cytochrome P450 eosinophil allergic orally AS 1810722 Inhibitor asthma IL-4 infiltration IFN-γ inhibitor